For those seeking comprehensive care, regenerative medicine in Chevy Chase, Maryland, provides a whole-body approach.
Living with chronic pain, fatigue, or limited mobility can significantly impact your quality of life. Whether it’s back pain, joint stiffness, or the effects of anxiety and depression, these challenges often reduce your ability to function daily. Fortunately, regenerative medicine offers innovative, non-invasive treatments to help you restore health, ease pain, and reclaim your independence.
CytoReason secures $80M funding to expand AI disease models and establish US hub
- By InnoNurse Staff -
Israel-based CytoReason has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to expand its AI disease models and establish a US hub in Cambridge, Massachusetts.
This investment will help CytoReason enhance its disease models, grow its proprietary data, and reduce R&D timelines for partner companies.
CytoReason's technology, used by six of the world’s top ten pharma companies, aids in making data-driven decisions in various therapeutic areas.
The funding supports CytoReason's aim to improve pharma R&D through predictive insights and data modeling.
Header image credit: CytoReason/Business Wire (a blue filter was added)
Scientists develop the first mouse model with a fully functional human immune system
- By InnoNurse Staff -
Scientists at The University of Texas Health Science Center at San Antonio have developed the first mathematical mouse model, called TruHuX (THX), with a fully functional human immune system and human-like gut microbiome.
Led by Dr. Paolo Casali, this breakthrough aims to enhance immunotherapy development and disease modeling. The project involved injecting immunodeficient mice with human stem cells from umbilical cord blood and using estrogen to support immune cell differentiation and antibody responses.
THX mice successfully mount antibody responses to vaccines and develop conditions like systemic lupus. This model offers new opportunities for human immune system studies, vaccine development, and therapeutic testing, potentially reducing the need for non-human primate research. The findings are published in the August 2024 issue of Nature Immunology.
Read more at UT Health San Antonio
///
Other recent news and insights
Saudi hospital achieves a 98% survival rate with robotic cardiac surgeries (Clinical Trials Arena)
